European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 146, Issue 2 , Pages 129-132 , October 2009

Cox-2 expression in ovarian malignancies: A review of the clinical aspects

Received 26 January 2009 ,Revised 26 May 2009 ,Accepted 28 May 2009.

References 

  1. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2 Suppl):28–35
  2. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Int Med. 2005;258:115–123
  3. Denkert C, Winzer KJ, Hauptman S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer. 2004;4:428–433
  4. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxogenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221–8227
  5. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?. Drugs. 2007;67:821–845
  6. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 2003;4:605–615
  7. Ohno S, Ohno Y, Suzuki N, Inagawa H, Kohchi C, Soma G, et al. Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res. 2005;25:3679–3687
  8. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol. 2008;109:140–145
  9. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529
  10. Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 2001;61:7305–7309
  11. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med. 2001;8:31–36
  12. Landen CN, Mathur SP, Richardson MS, Creasman WT. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003;188:1174–1176
  13. Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol. 2003;22:99–105
  14. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, et al. Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002;160:893–903
  15. Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A, et al. Expression of inducible nitric oxide synthase and cycloxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol. 2004;92:806–812
  16. Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer. 2005;15(255):60
  17. Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Acta Obstet Gynecol Scand. 2006;85:493–498
  18. Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and her-2/neu expression in ovarian cancer. Gynecol Oncol. 2002;85:305–310
  19. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol. 2002;13:1205–1211
  20. Ferrandina G, Ranelletti FO, Martinelli E, Paglia A, Zannoni GF, Scambia G. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer. 2006;6:182
  21. Erkinheimo TL, Lassus H, Finne P, et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER 2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res. 2004;10:538–545
  22. Erkinheimo TL, Sivula A, Lassus H, Heinonen M, Furneaux H, Haglund C, et al. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol. 2005;99:14–19
  23. Khalifeh I, Munkarah AR, Lonardo F, Malone J, Morris R, Lawrence WD, et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol. 2004;23:162–169
  24. Seo SS, Song YS, Kang DH, Park IA, Bang YJ, Kang SB, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol. 2004;92:927–935
  25. Ozel E, Pestereli HE, Simsek T, Erdogan G, Karaveli FS. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?. Int J Gynecol Cancer. 2006;16:549–555
  26. Singhal PK, Spiegel G, Driscoll D, Odunsi K, Lele S. Rodabaugh KJ. Cyclooxygenase 2 expression in serous tumors of the ovary. Int J Gynecol Pathol. 2005;24:62–66
  27. Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, et al. Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer. 2006;16(Suppl 1):247–253
  28. Li M, Qi SY, Wang Y, Feng SX, Zhang BZ, Wang R. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors. Arch Gynecol Obstet. 2005;2721:48–52
  29. Ferrandina G, Zannoni GF, Ranelletti FO, Legge F, Gessi M, Salutari V, et al. Cyclooxygenase-2 expression in borderline ovarian tumors. Gynecol Oncol. 2004;95:46–51
  30. Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphological changes in prophylactic oophorectomies. Cancer. 2003;98:2607–2623
  31. Fujimoto J, Toyoki H, Sakaguchi H, Jahan I, Alam SM, Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol Rep. 2006;15:21–25
  32. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer. 2003;98:1423–1429
  33. Ali-Fehmi R, Morris RT, Bandyopadhya S, Che M, Schimp V, Malone JM, et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol. 2005;192:819–825
  34. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275:14838–14845
  35. Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczynski M, Dietel M, et al. Significance of cyclooxygenase 2 and MDR1/P glycoporotein coexpression in ovarian cancers. Cancer Lett. 2006;235:272–280
  36. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P glyocprotein, DNA-topoisomerase, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol. 2004;94:152–160
  37. Vital-Reyes V, Rodriguez-Burford C, Chhieng DC, Oelschlager DK. Reyes Fuentes A, Barnes M, Grizzle WE. Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med ResV 37. 2006;689–695
  38. Barnes AP, Miller BE, Kucera GL. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol. 2007;104:443–450
  39. Munkarah AR, Genhai Z, Morris R, Baker VV, Deppe G, Diamond MP. Saed GM Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol. 2003;88:429–433
  40. Munkarah AR, Ali-Fehmi R, Jiang JZ, Elhammady E, Malone JM, Saed GM. The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer. Anticancer Drugs. 2007;18:889–896
  41. Barnes MN, Chhieng DF, Dreher M, Jones JL, Grizzle WE, Jones L, et al. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol. 2005;98:376–382
  42. Sørensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer. 2005;14(92):594–596
  43. Lacey JV, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer. 2004;1082:281–286
  44. Sumi T, Ishiko O, Yoshida H, Hyun Y, Nakagawa E, Hirai K, et al. Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. Int J Mol Med. 2001;8:495–498

PII: S0301-2115(09)00368-6

doi: 10.1016/j.ejogrb.2009.05.030

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 146, Issue 2 , Pages 129-132 , October 2009

Article Tools